UCLA (University of California, Los Angeles)
Welcome,         Profile    Billing    Logout  
 0 Trials 
20 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tran, Sandy
INVINCIBLE-3, NCT06263231: A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas

Recruiting
3
333
Europe, Canada, US
INT230-6, Eribulin, Trabectedin, Pazopanib
Intensity Therapeutics, Inc., Premier Research Group plc
Sarcoma,Soft Tissue
12/27
12/28
PRISM-MEL-301, NCT06112314: IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma

Recruiting
3
680
Europe, US, RoW
Brenetafusp, IMC-F106C, Nivolumab, OPDIVO, Nivolumab + Relatlimab, OPDUALAG
Immunocore Ltd
Advanced Melanoma
10/27
10/27
NCT06246110: A Phase 2 Study of EIK1001 in Combo with Pembrolizumab and Chemotherapy in Patients with Stage 4 NSCLC

Recruiting
2
70
US
EIK1001, Pembrolizumab, Paclitaxel, Pemetrexed, Carboplatin
Eikon Therapeutics
NSCLC
12/26
12/27
HARMONIC, NCT05456256: A Study of LP-300 with Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma

Recruiting
2
90
Japan, US, RoW
LP-300, Tavocept, BNP7787, Dimesna, Pemetrexed, Alimta, Pemfexy, Carboplatin, Paraplatin
Lantern Pharma Inc.
Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung
12/25
06/26
NCT05846659: Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies

Terminated
2
16
US
IMSA101, Immune checkpoint inhibitor, pembrolizumab, nivolumab, PULSAR
ImmuneSensor Therapeutics Inc.
Oligoprogressive
11/24
11/24
NCT05340309: Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

Recruiting
2
37
US
Atezolizumab and Recombinant Human Hyaluronidase, Atezolizumab + rHuPH20, Atezolizumab and Hyaluronidase, Atezolizumab with rHuPH20, Atezolizumab-rHuPH20, Atezolizumab/rHuPH20 Co-formulation, Recombinant Human Hyaluronidase Mixed with Atezolizumab, Tecentriq/rHuPH20, Survey Administration
University of Southern California, National Cancer Institute (NCI), Genentech, Inc.
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
12/25
12/26
EQUATE, NCT03763318: A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD

Completed
1b/2
30
US
EQ001, Bmab600, Itolizumab, EQ001 Placebo
Equillium, Biocon Limited
Acute-graft-versus-host Disease, aGVHD, GVHD, GVHD, Acute
11/22
11/22
MCLA-158-CL01, NCT03526835 / 2017-004745-24: A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Recruiting
1/2
523
Europe, US
MCLA-158, petosemtamab, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI, MCLA-158 + FOLFOX
Merus N.V., Merus N.V.
Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer
11/25
11/27
H-200-001, NCT04180215 / 2019-000907-34: A Phase 1/2 Study in Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Active, not recruiting
1/2
200
Europe, US
HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab., HB-202 / HB-201 alternating intravenous administration + pembrolizumab., HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab., HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)
Hookipa Biotech GmbH, Hookipa Biotech
HPV-Related Squamous Cell Carcinoma
06/25
06/26
Agni-01, NCT06060613: Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Recruiting
1/2
52
US
OBX-115
Obsidian Therapeutics, Inc.
Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer, Metastatic Lung Cancer, Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
10/25
10/27
NCT06338657: FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer

Recruiting
1
10
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, PEOX-based Polymer Encapsulated Paclitaxel FID-007, FID 007, FID-007, FID007, Nanoencapsulated Paclitaxel FID-007, Paclitaxel in Polyethyloxazoline Polymer, Tumor Resection
University of Southern California, National Cancer Institute (NCI)
Head and Neck Squamous Cell Carcinoma
04/26
04/27
NCT06420219: An Integrative Multi-Omic Characterization of Head and Neck Carcinogenesis, Progression and Recurrence

Recruiting
N/A
50
US
Non-Interventional Study
University of Southern California, National Cancer Institute (NCI)
Head and Neck Carcinoma
03/28
03/29
NCT06163534: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Head & Neck Squamous Cell Carcinoma (HNSCC)

Recruiting
N/A
500
US
Tempus AI, AstraZeneca
Head and Neck Squamous Cell Carcinoma
03/28
03/28
NCT04162678: Fluid Biopsy for the Diagnosis of Lung Cancer

Recruiting
N/A
75
US
Biospecimen Collection, Laboratory Biomarker Analysis, Liquid Biopsy, Plasma Biopsy, Medical Chart Review, Chart Review
University of Southern California, National Cancer Institute (NCI)
Lung Carcinoma
01/26
01/27
NCT03971266: Movement and Fitness Trackers in Determining Performance Status

Recruiting
N/A
68
US
Activity Monitor, Activity Tracker; Activity Tracker Device; Physical Activity Measuring Device, Media Intervention
University of Southern California, National Cancer Institute (NCI)
Malignant Neoplasm
03/25
03/26
Romano, Peggy
H-200-001, NCT04180215 / 2019-000907-34: A Phase 1/2 Study in Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Active, not recruiting
1/2
200
Europe, US
HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab., HB-202 / HB-201 alternating intravenous administration + pembrolizumab., HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab., HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)
Hookipa Biotech GmbH, Hookipa Biotech
HPV-Related Squamous Cell Carcinoma
06/25
06/26
LEADER, NCT04712877: Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers

Recruiting
N/A
1000
US
ctDNA, tumor NGS, FoundationOne CDx, FoundationOne Liquid
Lung Cancer Mutation Consortium, Lung Cancer Research Foundation
NSCLC
06/25
06/26
Naderi, Sahar
SCAD, NCT04496687: International Spontaneous Coronary Artery Dissection () "i" Registry

Recruiting
N/A
1000
US, RoW
SCAD Alliance, PERFUSE Study Group
Spontaneous Coronary Artery Dissection
12/25
12/25
Canan, Tim
SCAD, NCT04496687: International Spontaneous Coronary Artery Dissection () "i" Registry

Recruiting
N/A
1000
US, RoW
SCAD Alliance, PERFUSE Study Group
Spontaneous Coronary Artery Dissection
12/25
12/25
Iribarren, Ana
SCAD, NCT04496687: International Spontaneous Coronary Artery Dissection () "i" Registry

Recruiting
N/A
1000
US, RoW
SCAD Alliance, PERFUSE Study Group
Spontaneous Coronary Artery Dissection
12/25
12/25

Download Options